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ABSTRAK 
Rahmi A, Setiyono A, Juniantito V. 2015. Pengaruh kurkumin terhadap fibrosis paru-paru akibat aplikasi bleomisin pada Mus 
musculus. JITV 20(2): 148-157. DOI: http://dx.doi.org/10.14334/jitv.v20i2.1169 
Kurkumin merupakan bahan aktif utama dari tanaman kunyit (Curcuma longa) diketahui memiliki aktivitas sebagai anti-
oksidan dan anti-inflamasi. Bleomisin merupakan salah satu obat anti-kanker yang dapat menginduksi fibrosis paru-paru pada 
manusia dan hewan. Tujuan penelitian ini adalah untuk mengetahui efek biologis kurkumin pada fibrosis paru-paru yang 
diinduksi bleomisin pada mencit. Sebanyak 16 ekor mencit galur ddy dibagi dalam 4 kelompok perlakuan: (i) kontrol, 100 µl 
aquadest steril diinjeksikan secara SC, (ii) bleomisin (BLM), 100 µl bleomisin konsentrasi 1 mg/ml diinjeksikan secara SC, (iii) 
kurkumin (CMN), 100 µl aquadest steril diinjeksikan secara SC dan 100 mg/kg BB kurkumin dalam 0,5% 
carboxymethylcellulose (CMC) yang diinjeksikan secara IP, dan (iv) BLM+CMN, 100 µl bleomisin dengan konsentrasi 1 mg/ml 
diinjeksikan secara SC dan 100 mg/kg BB kurkumin dalam 0,5% CMC diinjeksikan secara IP. Semua perlakuan diberikan setiap 
hari selama 4 minggu. Organ paru-paru dikoleksi dalam 10% buffered neutral formalin (BNF). Pengamatan histopatogi dengan 
pewarnaan hematoksilin-eosin (HE) dan Masson’s trichrome (MT) untuk diamati tebal dinding alveol dan luas daerah jaringan 
ikat. Hasil penelitian menunjukkan bahwa pada kelompok perlakuan bleomisin (BLM) terjadi peningkatan luas jaringan ikat dan 
tebal dinding alveol secara signifikan jika dibandingkan dengan kontrol. Sementara itu, pemberian kurkumin pada mencit yang 
mendapatkan induksi bleomisin (kelompok BLM+CMN), menyebabkan terjadinya penurunan signifikan luas jaringan ikat dan 
tebal dinding alveol. Dapat disimpulkan kurkumin memiliki aktivitas sebagai inhibitor fibrogenesis untuk mengurangi keparahan 
fibrosis paru-paru akibat aplikasi bleomisin pada mencit.  
Kata Kunci: Bleomisin, Fibrosis Paru-paru, Mencit, Kurkumin 
ABSTRACT 
Rahmi A, Setiyono A, Juniantito V. 2015. Curcumin effect on Bleomycin-induced pulmonary fibrosis in Mus musculus. JITV 
20(2): 148-157. DOI: http://dx.doi.org/10.14334/jitv.v20i2.1169 
Curcumin, a curcuminoid compound of turmeric has been demonstrated to have anti-oxidant and anti-inflammatory 
properties. Bleomycin (BLM) is an anti-cancer drug induced pulmonary fibrosis in human and animals. This study was aimed to 
investigate biological effects of curcumin on bleomycin-induced pulmonary fibrosis in mice (Mus musculus) through 
pathomorphological assessment. In this study, 16 mice ddy strain were divided into four groups, namely (i) control, mice were 
subcutaneously (SC) injected with 100 µl sterilized aquadest in dorsal skin, (ii) BLM group, injected SC with 100 µl of 1 mg/ml 
BLM in dorsal skin, (iii) Curcumin (CMN) group, mice were intraperitoneally (IP) injected with 100 mg/kg body weight (BW) 
curcumin dissolved in 0,5% carboxy methyl cellulose (CMC) and injected with 100 µl sterilized aquadest SC, (iv) BLM+CMN 
group, injected SC with 100 µl of BLM 1 mg/ml and injected IP with 100 mg/kg BW CMN in 0,5% CMC. All treatments were 
performed daily for four weeks period. The lung samples were collected and fixed in buffered neutral formalin (BNF) 10%. 
Histopathological evaluation was performed with hematoxylin-eosin (HE) and Masson’s trichrome (MT) stains. The results 
showed that BLM treatment significantly increased fibrosis area and alveolar wall area fraction as compared to control. OIn the 
other hand, CMN treatment significantly reduced fibrosis area and alveolar wall area fraction in mice treated with BLM. In 
conclusion, our study showed that CMN treatment may inhibit lung fibrogenesis in BLM-induced pulmonary fibrosis.  
Key Words: Bleomycin, Curcumin, Mice, Pulmonary Fibrosis 
INTRODUCTION 
Pulmonary fibrosis is a chronic pulmonary disease 
characterized by pathological lesions in the form of 
extracellular matrix and tissues component changes, 
followed by clinical symptoms, physiological disorders, 
and radiographic findings (Todd et al. 2012). Many 
factors cause this pulmonary fibrosis, such as it is 
exposured by air poison, particular pulmonary disease, 
effect of radiation therapy and chemotherapy (Ley & 
Collard 2013). 
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Bleomycin (BLM) is used as a chemotherapy agent 
for various cancers. This antibiotic of antitumor is a 
derivative glycopeptide isolated from Streptomyces 
verticillus (Yamamoto 2010). BLM has strong 
antitumor activity. Clinically, BLM is used as tumor 
therapy such as squamous cell carcinoma at around 
head and neck (including mouth, tongue, tonsils, 
nasopharynx, oropharynx, sinus, palate, lips, buccal 
mucosa, the gums, the epiglottis, and larynx), malignant 
lymphoma, testicular carcinoma, and malignant pleural 
effusion (Chu et al. 2010). 
The main limitation of BLM therapy is its side 
effect which causes alveolitis fibrosis (Matsushita et al. 
2008). Frusch et al. (2012) said that there are several 
syndromes in the lung linked with BLM utilization, that 
is bronchiolitis obliterans, hypersensitivity eosinophils, 
and interstitial pneumonitis which will thrive become 
pulmonary fibrosis. Besides, BLM-induced pneumonitis 
can reach 46% in patients who receive BLM treatment. 
Mortality level of the pulmonary fibrosis disease is 
around 10-20% with 2-3% from patients treated by 
BLM. Brugge et al. (2013) said that BLM therapy side 
effect could cause pneumonitis. 
Fibrosis mechanism in lung due to the side effect of 
BLM utilization has not known. Some factors that have 
role in pulmonary fibrosis in BLM therapy are oxidative 
stress, BLM-hydrolase enzyme deactivation, genetic, 
and the release of inflammatory cytokines (Brugge et al. 
2013; Reinert et al. 2013). BLM use in human also 
causes other side effect, such as an abnormality skin 
characterizes the scleroderma (Juniantito et al. 2013). 
Fibrosis pathogenesis (fibrogenesis) is divided in 
several overlapping phases, namely inflammation, 
connective tissue proliferation, and intractable fibrosis 
(Matsushita et al. 2008; Reinert et al. 2013). 
Retardation in one step of fibrogenesis causes a 
decreasing of connective tissue formation (Loomis-
King et al. 2013). BLM could stimulate endothelial 
cells, macrophages, and fibroblasts to induce synthesis 
of inflammatory mediators especially proinflammatory 
and fibrogenic cytokines, inducing apoptosis, and free 
radicals synthesis (Yamamoto 2010; Yamamoto & 
Katayana 2011). It was thought that prevention of 
fibrosis might be mediated by inhibition of 
inflammation with anti-inflammatory substances 
(Basnet & Skalko-Basnet 2011; Kardena & Winaya 
2011). 
Curcumin (diferuloylmethane) is an active 
ingredient in turmeric, in addition, it is also known as 
an antioxidant (Zhang et al. 2011). Turmeric is widely 
available plant in Indonesia which is used often as spice 
and herbal ingredient. Anti inflammation effect of 
curcumin is likely because of a high pleiotropic 
molecule which able to interact with and related to the 
most transcription factors in inflammatory mediators 
synthesis and inhibiting free radicals releasing in the 
inflammatory cells (Jurenka 2009; Marçal et al. 2012). 
Some studies have been conducted to determine 
curcumin effect as anti-inflammation and its potential to 
prevent the fibrosis (Jurenka 2009; Beevers & Huang 
2011; Kardena & Winaya 2011). Curcumin can 
decrease fibrosis level in liver, kidney, and lung of 
laboratory animal (Beevers & Huang 2011). Therefore, 
curcumin can be used as potential candidate of anti-
fibrosis preparate, especially in pulmonary fibrosis. 
This study was aimed to see the curcumin potential in 
preventing the side effect of BLM use in cancer patients 
who are undergoing a chemotherapy. 
MATERIALS AND METHODS 
Time and place 
This study was conducted during December 2014 - 
March 2015 in Laboratory Animals Management Unit 
(UPHL), Faculty of Veterinary Medicine, Bogor 
Agricultural University and Histopathology Laboratory, 
Pathology Division, Faculty of Veterinary Medicine, 
Bogor Agricultural University. 
Inducer material of pulmonary fibrosis 
Bleocin (Bleomycin hydrochloride 15 mg, Kalbe 
Farma, Jakarta, Indonesia) was diluted in 15 ml sterile 
aquadest to reach concentration of 1 mg/ml. As much as 
100 µL of the solution was injected subcutaneously 
(SC) on the back skin for BLM and BLM+CMN group 
everyday for 4 weeks. 
Curcumin 
Curcumin active ingredients (Biopurify, Chengdu, 
China) was diluted in 0.5% carboxymethylcellulose 
(CMC) and injected 100 mg/kg of body weight by 
intraperitoneal injection (IP) in CMN and BLM+CMN 
group everyday for 4 weeks. 
Experimental procedure  
All of procedures conducted in this study met the 
requirement of Animal Ethics Commission of Bogor 
Agricultural University Number 25-2014 IPB. Sixteen 4 
weeks old male ddy strain mice with body weight 
around 20-25 gram (The National Agency of Food and 
Drug Control (NA-DFC), Jakarta, Indonesia) were used 
and divided into 4 groups. There were 4 mice in each 
group.  
This study was divided into 4 treatment groups, 
namely: (i) control, injected subcutaneously by 100 µL 
sterile aquadest in the back skin, (ii) BLM, injected 
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subcutaneously in the back skin with 100 µL BLM of 1 
mg/mL concentration, (iii) CMN, injected 
subcutaneously with 100 µL sterile aquadest in the back 
skin and injected intraperitoneally with curcumin of 100 
mg/kg of body weight in 0.5% CMC, and (iv) 
BLM+CMN, injected subcutaneously with 100 µL 
BLM of1 mg/mL concentration and injected 
intraperitoneally with curcumin of 100 mg/kg of body 
weight in 0.5% CMC. Injection of the curcumin by 
intraperitoneal injection was adapted from Li et al. 
(2013). 
This study was done in three steps, namely: (i) 
acclimatization, the experimental animals were adapted 
in new cage for 2 weeks, (ii) treatments, the 
experimental animals were treated in accordance to the 
respective groups everyday for 4 weeks, (iii) 
termination, the experimental animal were euthanized 
by giving Ketamine HCL of 0.2 mL/head (AVMA 
2013). Furthermore, left lobus of lung was collected to 
be made histopathology preparates, then stained by 
hematoxylin-eosin (HE) for observation of tissue 
structure of the lung (Fischer et al. 2006) and 
Masson’strichrome (MT) to see the presence of 
connective tissue (Suvik & Effendy 2012). 
Histopathological assesment by HE and MT stains 
Lung of BNF 10% was sliced in 3 mm and inserted 
into tissue cassette for dehydration process, clearing 
and paraffin infiltration using automatic tissue 
processor. Chunk organs, further was printed in the 
paraffin until paraffin block formed. For histology test, 
the paraffin block was sliced by rotary microtome in 3-
5 μm of thickness. Cutting results were placed in object 
glass to be deparafinized and rehydrated for tissue 
staining by hematoxylin-eosin and Masson’s trichrome. 
All of the cutting results were observed by a light 
microscope which was connected to the computer. 
Observed parameters of this organ were connective 
tissue width and alveoli wall thickness. 
Connective tissue width 
Connective tissue width was quantitatively counted 
by Image J software (http://imagej.nih.gov//ij/; NIH, 
Maryland, USA), by analyzing tissue slide which has 
stained by modification of MT stains (Suvik & Effendy 
2012). Image J software utilization is to decrease the 
level of counting subjectivity by scoring method. By 
using 40x objective lens magnification, as much as 20 
visual fields per treatment group randomly selected by 
video camera (Indomikro HDMI camera) which was 
shown on colored screen. The width of each visual field 
was 326.40×184.00 µm2. Furthermore, figure was 
customized for contrast, brightness, and threshold color. 
Image analysis program detected the width of blue area 
which indicates collagen area or connective tissue in 
each visual field and presented in the form of 
percentage. 
Alveolar wall thickness 
Alveoli wall thickness quantitatively was counted 
by analyzing tissue slide which has been stained by HE. 
As much as 20 visual fields per treatment group were 
randomly selected using video camera showed on the 
colored screen. The wide of each visual field was 
326.40×184.00 µm2. Alveoli wall thick measurement 
was done 10 times of every visual field, and the data 
presented in the form of average. 
Data analysis 
Percentage of width of connective tissue and alveoli 
wall thickness were analyzed by SAS 1.9 software for 
MicrosoftWindows ANOVA and presented in form of 
average and standard deviation. Further, Duncan 
advance test was done to determine whether there is a 
significant differences between the treatments or not. 
RESULT AND DISCUSSION 
Histology Result by Hematoxylin-Eosin Staining 
Figure 1 is photomicrography of lung tissue of each 
treatment. Figure 1A is a photomicrography of control 
group of lung tissue. In this figure, normal alveoli wall 
structure is 3.7±0.6 μm. The same thing occurred in 
CMN group (Figure 1C). It is shown that lung with 
normal alveoli wall structure of 3.4±0.5 μm.  
Figur 1B is a photomicrography of BLM group. In 
this group, it is shown an inflammation accompanied by 
an increase in cell number in interstitium, therefore 
alveoli wall become thicker (24.9±6.3 μm) than the 
control group. Besides, there was an infiltration of 
inflammatory cells dominated by macrophages and 
lymphocytes. Alveoli wall thickening resulted in width 
of alveoli area became smaller, therefore the air entered 
the lung became limited. Rienert et al. (2013) said that 
thickening of the alveoli wall would cause difficulty in 
breathing (anoxia). In the BLM+CMN group (Figure 
1D), it is shown lesion similar to the BLM group, that is 
the presence of inflammation, increasing in cell number 
in interstitial and the thickening of the alveoli wall 
(9.9±2.6 μm) with lower severity compared to the BLM 
group. 
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Figure 1. Photomicrography of lung tissues by HE staining of each treatment group: Control (A); BLM (B); CMN (C); and 
BLM+CMN (D) 
 
 
 
Figure 2. Photomicrography of lung tissues by MT staining of each treatment group: Control (A); BLM (B); CMN (C);  
BLM+CMN (D) 
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Yamamoto & Nishioka (2000) said that in mice 
everyday induced by BLM SC for 4 weeks, there was 
pulmonary fibrosis characterized by mononuclear cell 
infiltration, ederma, and septum alveolar thickening due 
to decrease in number of macrophages alveolar and 
lymphocyte. Besides, Izbicki et al. (2002) found that 
there were perivascular and lymphocytes peribronkial 
(day 3), subcapsular fibrosis (day 6), and decreasing in 
number of macrophages alveolar and septum alveolar 
(day 14) in mice’s lung histology induced by pulmonary 
fibrosis with single dose BLM by intratracheal. 
Histology result by Masson’s Trichrome (MT) 
staining 
Tissue staining techniques by MT is addressed to 
identify the presence of the connective tissue or 
collagen in the tissue. Result of the lung tissue staining 
by MT technique was presented in Figure 2. 
Figure 2A (control) and 2C (CMN) shows normal 
structure of lung tissues with thin alveoli wall (3.7±0.6 
μm). In the two figures do not show an excessive blue 
structure, indicating that in the two group there is no 
excessive collagen accumulation. On the contrary, 
figure 2B (BLM) shows blue accumulation which 
extends almost to the entire visual field. The blue color 
on lung slide colored by MT indicating the presence of 
accumulation connective tissue or collagen (Suvik & 
Effendy 2013). Besides, in the BLM group was also 
seen smaller alveoli diameter compared to the control 
group. Figure 2D (BLM+CMN) shows light 
accumulation of collagen visualized by blue color and 
looked like thickening of the alveoli wall. 
Width of connective tissue 
Measurement of connective tissue width in the lung 
was done to determine extent of lung tissue damage due 
to BLM application. In figure 3, it is not seen the 
presence of a significant differences of the connective 
tissue between control group (2.4±0.8%) and CMN 
group (1.5±0.6%). However, in BLM group 
(15.0±2.4%), there was significantly wider connective 
tissue value (P<0.05) compared to control group. In the 
BLM+CMN group (6.2±2.0%), there was significantly 
lesser width connective tissue (P<0.05) compared to the 
BLM group. This research result was in line with 
Izbicki et al. (2002) that there was an increase in 
connective tissue width of mice lung induced by single 
dose Bleomycin by intratracheal. Besides, Liu et al. 
(2013) also reported that there were an inflammation 
and fibrosis in interstitial of mice lung tissue induced by 
BLM through intratracheal. 
Wide development of connective tissue in BLM 
group was caused by BLM activity which may induce 
pulmonary fibrosis by causing inflammation, than it 
developed become proliferation of fibroblast. Fibroblast 
is a cell which produced extracellular matrix (Todd et 
al. 2012). Yamamoto & Katayama (2011) said that 
BLM can stimulate endothelia cell, macrophage, and 
fibroblast to induce inflammatory mediator. The 
inflammatory mediator will induce proinflammatory 
cytokines, cytokine fibrogenic, transforming growth 
factor-β (TGF-β), apoptosis, and the release of free 
radicals.  
 
 
Figure 3. The wide of connective tissue of each treatment group, different superscript word shows significant difference (P<0.05) 
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Reinert et al. (2013) reported that low BLM-
hydrolase enzyme activity can be a predisposing factor 
of pulmonary fibrosis due to the BLM application. 
Through in vivo, the BLM will be metabolized become 
non-toxic molecule with Bleomycin-hydrolase enzyme 
help (Haston et al. 2002). This enzyme is cytosolic 
aminopeptidase group which has low activity in lung 
and skin (Reinert et al. 2013). Therefore, BLM 
application may cause the pulmonary fibrosis. The 
fibrosis in the lung is started by an inflammatory. The 
inflammatory will develop into proliferation of 
fibroblasts into myofibroblast (cell produces collagen), 
and it finished by persistent formation of connective 
tissue. Mechanism of fibrosis induction by BLM was 
caused by increasing secretion of extracellular matrix 
proteins because of cytokine fibrogenic effect which 
was released by macrophages, endothelial cells, and 
fibroblasts (Reinert et al. 2013). Besides, BLM in the 
cells will bind with iron ion (Fe+2) and oxygen forming 
Fe+3 ion which produce the free radicals, so that cause 
DNA damage, RNA degradation, and inducing the 
apoptosis (Yamamoto 2010). Moreover, the free 
radicals or reactive oxygen species can produce direct 
toxicity through participation in redox reactions and 
subsequent fatty acid oxidation, which leads to 
membrane instability. Oxidant can cause inflammatory 
reaction within be lung. The inflammatory mediators 
like cytokines such as interleukin-1, macrophage 
inflammatory protein-1, platelet-derived growth factor, 
and TGF-β are released from alveolar macrophages in 
animal models of bleomycin toxicity, resulting in 
fibrosis. Damage and activation of alveolar epithelial 
cells may result in the release of cytokines and growth 
factors that slimulate proliferation of myofibroblast and 
secretion of pathologic extracellular matrix, leading to 
fibrosis. 
The inflammation due to BLM application will 
cause body to response to repair the tissue by involving 
connective tissue reconstitution from the fibroblast into 
myofibroblast (Reinert et al. 2012). Myofibroblast is the 
main component in fibrosis process or wound healing. 
This myofibriblast will produce extracellular matrix, so 
it will cause extracellular matrix proteins accumulation. 
Previous study conducted by Xu et al. (2009) showed 
that TGF-β is cytokine inducer of differentiation of 
fibroblast cell into myofibroblast cell. Yamamoto & 
Nishioka (2004) presented that several actions of TGF-
β are, among other as chemotactic macrophages and 
fibroblasts, stimulating fibroblast proliferation, 
increasing extracellular matrix synthesis, decreasing 
extracellular matrix proteinase regulation, and 
increasing proteinase inhibitor regulation. So that 
exacerbates the development of fibrotic lesions in the 
lung. 
The opposite occurred in BLM+CMN group where 
there was a significant decrease (P<0.05) of width of 
connective tissue compared to the BLM group (Figure 
3). In line with Punithavathi et al. (2000) that there was 
a decreasing of alveolar macrophage amount, 
superoxide and nitrikoksida in rats given oral curcumin 
treatment after single dose Bleomycin induction by 
intratracheal. So, in his research, it was concluded that 
curcumin was a potential material as an anti-
inflammatory and anti-fibrogenic in BLM-induced 
pulmonary fibrosis. 
Bleomycin as an antibiotic antitumor agent, widely 
used for livestocks, such as pig (Balazs et al. 1994) and 
sheep (Organ et al. 2015). Same as in laboratory 
animals, BLM utilization in pig and sheep also caused 
side effect such as an inflammation into pulmonary 
fibrosis (Balazs et al. 1994; Organ et al. 2015). 
Pathogenesis mechanism of pulmonary fibrosis due to 
BLM application in livestocks was alike with the 
laboratory animals, so that was possible to be given 
curcumin as anti-inflammation and antioxidant to 
reduce fibrogenesis severity in the pulmonary fibrosis 
cases due to BLM application. 
The decreasing of width of lung connective tissue in 
this study may be caused by 2 factors. First, the 
curcumin can directly inactivate the bleocymin activity, 
so that inflammation did not occur. Second, activity of 
anti-inflammation from the curcumin causes the 
inflammation become lower, so that fibrosis can be 
pressed. The second one is closer with pathogenesis of 
fibrosis inhibition by the curcumin. This was caused by 
BLM induction and curcumin therapy conducted 
through 2 different ways. Bleomycin induction was 
done subcutaneously, whereas curcumin therapy was 
done by intraperitoneal. Both of subcutaneous and 
intraperitoneal ways will interact systematically in the 
body, so that increasing width of lung connective tissue 
due to Bleomycin application possibly hampered by 
anti-inflammation activity from the curcumin. Besides, 
the curcumin was known to have effectiveness as an 
inhibitor receptor TGF-β, so that TGF-β production can 
be inhibited (Mo et al. 2012). 
Prasad et al. (2014) said intraperitonel injection of 
curcumin more often applied to animals than to human. 
Besides, the bioavailability compound of curcumin via 
intraperitoneal injection is higher than gavage. 
Interestingly, oral curcumin treatment showed no effect 
on important measure of BLM-induced injury in mice, 
whereas intraperitoneal curcumin administration 
effectively inhibited inflammation and collagen 
deposition along with a trend toward improved survival 
of animal, and also reduced fibrotic progression even 
when administered after the acute bleomycin-induced 
inflammation had subsided (Smith et al. 2010). 
Smith et al (2010) said that curcumin administration 
could significantly prevent lung inflammation and 
collagen deposition in pulmonary fibrosis induced by 
BLM by intratracheal. Curcumin was high pleiotropic 
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molecule which able to interact and bind with the most 
of inflammation molecule target (Jurenka 2009; Marçal 
et al. 2012). Curcumin has been reported having activity 
as an anti-cancer (Wiken et al. 2011), anti-oxidant 
(Bhullar et al. 2013) and anti-inflammation (Basnet & 
Skalko-Basnet 2011). Turmeric bioactive compounds 
had protective effect to heart cell which exposed to 
toxic chemicals such as tetrachloride (CCl4) (Prakash et 
al. 2008; Kardena & Winaya 2011). Yu et al. (2011) 
reported that curcumin administration can reduce 
pancreatic tissue damage and another organs due to 
caerulein induction through inhibiting the release of 
inflammatory mediator of TNF-α cytokines. 
Curcumin has been reported to exhibit anti-
tumorigenic and chemo-preventive activities due to the 
structural resemblance of dibenzoyilmethane (DBM) to 
the anti-inflammatory and aspirin-like skeleton of DBM 
derivates (Lin et al. 2011). Villegas et al. (2011) 
reported curcumin has also demonstrated protective and 
preventive effect in progression of colorectal colitis 
cancer, which was collerated with a lowered immune-
reactivity of beta-catenin and reduction of pro-
inflammatory cytokine levels and a decrease of 
inflammatory mediator’s overexpression.  
Lee et al. (2010) evaluated that curcumin as a 
potential dietary supplement in the setting of thoracic 
radiotherapy in mice with creating a baseline 
radioprotective state prior to irradiation by inducing 
protective gene expression as well as having potent 
direct antioxidant scavenging activity. Li et al. (2013) 
said curcumin application has a protective effect on the 
acute hepatic injury induced by acetaminophen with 
reduced acetaminophen-induced hepatocyte apoptosis 
and that protection may be related to its inhibition of 
lipid peroxidation and oxidative stress. 
Thickness of alveolar wall 
Figure 4 shows that there is no significant difference 
of alveolar wall between control group (3.7±0.6 μm) 
and CMN group (3.4±0.5 μm). However, there was 
significantly (P<0.05) higher alveolar wall thickness 
value in BLM group (24.9±6.3 μm) compared to the 
control group. In BLM+CMN group (9.9±2.6 μm) there 
was significantly (P<0.05) lower alveolar wall thickness 
value compared to BLM group. 
The results about width of connective tissue and 
alveolar wall thickness in each treatment group were 
presented in Table 1. 
This research result is aligned with a research of 
Izbicki et al. (2002) where alveolar wall thickening in 
mice lung tissue induced by single dose BLM by 
intratracheal. Alveolar wall thickening in BLM group
 
Figure 4. The Alveolar wall thickness in each treatment group, different superscript word shows significantly (P<0.05) difference 
Table 1. Result of the wide of connective tissue and alveolar wall thickness 
Treatment Group Wide of connective tissue (%) Alveolar wall thickness (µm) 
Kontrol 2.39±0.78a 3.72±0.56a 
BLM 15.03±2.45b 24.93±6.26b 
CMN 1.50±0.61a 3.39±0.54a 
BLM+CMN 6.17±2.01c 9.95±2.60c 
Different superscript in one same column shows significantly difference (P<0.05) n= 4  
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was caused by BLM administration continuously every 
day, which eventually caused chronic type lesio 
forming. The BLM continuous administration caused 
formation of progressive pulmonary fibrosis lesion 
(Schwaiblmair et al. 2012; Reinert et al. 2013). Increase 
wall thickness was caused by the existence of the 
fibrosis, besides it can also caused by interstitial edema 
(Izbicki et al. 2002). 
In this study, Bleomycin toxicity was caused by low 
activity of BLM-hydrolase enzyme in the lung causing 
the BLM not metabolized into intoxic molecule form. 
Reinert et al. (2013) said that low activity of BLM-
hydrolase enzyme in the lung resulted in an excessive 
apoptosis. Besides, the BLM can also stimulate 
endothelial cell, macrophage, and fibroblast to induce 
inflammatory mediator, apoptosis, and free radicals 
(Yamamoto & Katayama 2011). The most common 
symptomps from bleomycin-induced hypersensitivity 
pneumonitis are exertional dispnea and non-productive 
cough, with progressive pneumonitis dyspnea at rest, 
tachypnea, and cyanosis may occur (Sleijfer 2001).  
Bleomycin is one of xenobiotis which able to induce 
radical oxygen synthesis excessively such as 
superoxide, hydrogen peroxide, peroxynitrite and 
hydroxyl radicals which is the mean mediator in 
inflammatory process in the lung (Oury et al. 2001). 
The inflammation will cause inflammatory cells 
entering the tissue and releasing cytokine inflammation 
mediator (Reinert et al. 2013). Furthermore, the 
cytokine caused fibroblast proliferation into 
myofibroblast. This inflammation and fibroblast 
proliferation will cause an increase of alveolar wall 
thickness to the pulmonary fibrosis (Izbicki et al. 2002). 
Curcumin administration significantly press alveolar 
wall thickness incidence. The curcumin can press 
apoptosis and inflammation incidence; this is related to 
its activity as anti-oxidant and anti-inflammation (Smith 
et al. 2010; Bhullar et al. 2013; Basnet & Skalko-Basnet 
2011). Smith et al. (2010) presented that curcumin 
administration significantly press pulmonary 
inflammation and collagen deposition in the pulmonary 
fibrosis induced by BLM.  Punithavathi et al. (2000) 
said that the curcumin mediated the reduction of total 
number of broncho-association limfoid follicles 
(BALF) cell by preventing inflammatory cell crossing 
endotel and epithelial basal membrane towards the 
inflammation location. This is because of the curcumin 
stabilized the endotel and epithelial basal membrane. 
Therefore, the curcumin activity as anti-oxidant and 
anti-inflammation can press alveolar wall thickness 
incidence in the lung due to BLM administration. 
CONCLUSION 
Curcumin administration can inhibit fibrogenesis in 
mice pulmonary fibrosis due to the BLM application. 
This information can be used as first information to 
prevent side effect of BLM utilization to cancer patients 
who has to undergo chemotherapy. 
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